Pharmaceuticals

Eli Lilly

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Eli Lilly and other Fortune 500 pharmaceutical giants establish a presence in Beijing International Pharmaceutical Innovation Park

Report claims Trump purchased Eli Lilly stock during period of favorable government policies

Investment firm GLOBALT increases its stake in Eli Lilly and Company

Multiple analyst firms update ratings and earnings forecasts for Eli Lilly

Eli Lilly's Q1 2026 revenue soars 56%, topping global pharmaceutical sales charts

Eli Lilly and Company to Participate in EASD Industry Symposium

Institutional Investors Show Mixed Changes in Eli Lilly Holdings

Eli Lilly Announces Additional $4.5 Billion Investment to Expand US Manufacturing Capacity for Weight-Loss Therapies

Multiple institutional investors increased their stakes in Eli Lilly and Company during the recent reporting period.

Eli Lilly is expected to release pivotal Phase 3 clinical trial data for its highly anticipated obesity drug, Retatrutide.

Millennium Capital Advisors takes a new $3.94 million position in Eli Lilly, report says

Eli Lilly gains attention for positive trial data on its next-generation weight-loss drug, Retatrutide.

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Eli Lilly and Company (LLY.US) Q1 2026 Earnings Conference Call

Eli Lilly and Company (LLY.US) Q4 2025 Earnings Conference Call

Eli Lilly and Company (LLY.US) Q3 2025 Earnings Conference Call

Eli Lilly and Company (LLY.US) Q2 2025 Earnings Conference Call

Eli Lilly and Company (LLY.US) Q1 2025 Earnings Conference Call

Eli Lilly and Company (LLY.US) Q4 2024 Earnings Conference Call

Eli Lilly and Company (LLY.US) 2024 Third Quarter Earnings Conference Call

IBBQ

ELIS

ELIL

LABU

LLYX

The U.S. Supreme Court denied Eli Lilly's petition, finalizing a $220M judgment for defrauding the Medicaid Drug Rebate Program. This marks a significant victory for whistleblower Ronald J. Streck and his legal team after a 12-year legal battle. The case, initiated in 2014, revealed that Eli Lilly failed to pay required Medicaid rebates following price increases. This decision upholds a unanimous jury verdict and highlights the success of False Claims Act litigation.

prnewswire

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Direxion Daily LLY Bear 1X Shares

Health Care Select Sector SPDR

Direxion Daily LLY Bull 2X Shares

Proshares Ultra Nasdaq Biotech

VG Health

iShares US Pharma

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Defiance Daily Target 2X Long LLY ETF

ALPS Medical Breakthrough

07:27 ETWMHW Secures Victory; U.S. Supreme Court Denies Eli Lilly's Petition for Certiorari, Finalizing $220M+ False Claims Act Judgment

LLYZ

The U.S. Supreme Court has rejected Eli Lilly's appeal regarding a $194 million whistleblower judgment for underpaying Medicaid rebates by misreporting drug pricing. The decision upholds the federal False Claims Act, allowing private individuals to sue on behalf of the government. Eli Lilly's stock fell 1.64% to $988.42 following the ruling, with the company arguing that the whistleblower's claims were unfounded and that its pricing practices were industry-standard.

Fidelity

Defiance Daily Target 2X Short LLY ETF

S&P 500

Ondas

Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case

Caliway Biopharmaceuticals presented preclinical data for its fat-reduction candidate CBL-514 combined with GLP-1 drugs at the European Congress on Obesity 2026. The studies showed enhanced weight-loss effects and potential metabolic benefits. The same data will be presented at the American Diabetes Association’s 2026 Scientific Sessions, with plans for human clinical studies this year, aiming for partnerships in obesity treatments.

PUBT

Caliway touts preclinical CBL-514 combo data with semaglutide, tirzepatide at ECO 2026

The company is riding an incredible tailwind.

iShares Global Healthcare

Eli Lilly stock: Next stop $2,000?

Eli Lilly has partnered with Caitlin Clark’s foundation to open three multisport community courts in Indianapolis, including two at public schools and one in a park. This initiative is part of Lilly's 150th anniversary celebrations, with the courts designed for basketball, soccer, and futsal. The project involves Musco Lighting and aims to enhance community access to sports facilities. Lilly's campaign, '150 Years of Everything Else,' promotes its brand through various media.

Fiercepharma

Lilly allies with Caitlin Clark for Indianapolis sports courts

GBTC

SBFM

The stock market opened with significant movements: Sunshine Biopharma (SBFM) surged, while Bitcoin Depot (BTM) plummeted due to bankruptcy. Eli Lilly (LLY) fell after a Supreme Court decision, and SpaceX plans a stock split. Boston Scientific (BSX) announced a share buyback, and Costco (COST) hit a 52-week high. Other notable changes included declines for Meta (META) and Advanced Micro Devices (AMD), while Netflix (NFLX) rose on positive analyst coverage.

- The trading week has begun with significant movements in various stocks, including a massive rally for Sunshine Biopharma (SBFM) and volatility for Redwire (RDW).  
- Notable declines include Bitcoin Depot (BTM) following a bankruptcy filing, while Costco Wholesale (COST) reached a new 52-week high due to a dividend increase.  
- Overall, the Dow Jones (DJIA) experienced a dip amidst rising oil prices and mixed performances across tech and retail sectors.

Eli Lilly(LLY.US)

07:27 ETWMHW Secures Victory; U.S. Supreme Court Denies Eli Lilly's Petition for Certiorari, Finalizing $220M+ False Claims Act Judgment

Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case

Caliway touts preclinical CBL-514 combo data with semaglutide, tirzepatide at ECO 2026

Eli Lilly stock: Next stop $2,000?

Lilly allies with Caitlin Clark for Indianapolis sports courts

Morning News Wrap-Up, 5/18/26: Today's Biggest Stock Market Stories!